Get the Stockscreener App
139.98
0.15%
-0.21
Pre-market:
139.92
-0.06
-0.04%
Biogen Inc stock is traded at $139.98, with a volume of 1.25M.
It is down -0.15% in the last 24 hours and up +1.11% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$140.19
Open:
$140.36
24h Volume:
1.25M
Relative Volume:
0.86
Market Cap:
$20.49B
Revenue:
$9.61B
Net Income/Loss:
$1.62B
P/E Ratio:
12.64
EPS:
11.07
Net Cash Flow:
$1.77B
1W Performance:
-5.01%
1M Performance:
+1.11%
6M Performance:
-28.45%
1Y Performance:
-38.22%
1-Day Range:
$139.05
$143.50
1-Week Range:
$139.05
$157.09
52-Week Range:
$128.51
$238.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
139.98 | 20.49B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
801.65 | 720.02B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
211.55 | 373.46B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.99 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
75.89 | 336.88B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
94.71 | 251.88B | 64.17B | 17.12B | 18.10B | 6.73 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Edgestream Partners L.P. Increases Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Wealthfront Advisers LLC - MarketBeat
Multiple Sclerosis Therapeutics Market Projected To Witness Substantial Growth, 2025-2032: Biogen Inc., - EIN News
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Daiwa Securities Group Inc. - MarketBeat
20,831 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by AlphaQuest LLC - MarketBeat
Amundi Raises Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Marathon Trading Investment Management LLC Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
M&T Bank Corp Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant - Nasdaq
X-Elio inks VPPAs with Cisco, Biogen, others for 172 MW of US solar - Renewables Now
X-ELIO closes six US PPAs with Cisco, Biogen, IDEXX, and Waters Corporation - PR Newswire
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR - Yahoo Finance
18,715 Shares in Biogen Inc. (NASDAQ:BIIB) Bought by Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD - MarketBeat
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD Makes New $8.34 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
AMF Tjanstepension AB Has $9.04 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Victory Capital Management Inc. Trims Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - MSN
Biogen Stock Is Mutating Into a Value Play - MSN
Stephen A. Sherwin Sells 8,760 Shares of Biogen Inc. (NASDAQ:BIIB) Stock - MarketBeat
Biogen to Participate in the Stifel 2025 Virtual CNS Forum - Biogen | Investor Relations
Sage Therapeutics stock rated Underperform at BofA (SAGE) - Seeking Alpha
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed - MSN
Biogen Initiates Dosing of Phase 3 Study of Felzartamab -March 11, 2025 at 09:47 am EDT - Marketscreener.com
Biogen patents new GPR17 antagonists for multiple sclerosis - BioWorld Online
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients - Biogen | Investor Relations
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication - StockTitan
Biogen Target of Unusually Large Options Trading (NASDAQ:BIIB) - Defense World
Biogen Director Makes a Major Stock Move! - TipRanks
Candriam S.C.A. Has $30.88 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Bought by E Fund Management Co. Ltd. - MarketBeat
Biogen director Stephen Sherwin sells shares for $1.31 million - Investing.com
Decoding Biogen's Options Activity: What's the Big Picture? - Benzinga
A Mother's Love and Daughter's Fight: Facing Alzheimer's Together - CBS News
Investors Purchase Large Volume of Biogen Put Options (NASDAQ:BIIB) - MarketBeat
What’s driving pharma’s layoffs in 2025 - PharmaVoice
Oppenheimer & Co. Inc. Sells 1,826 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mutual of America Capital Management LLC Has $2.68 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Leigh Syndrome Treatment Market Poised for Substantial Growth - openPR
State of Michigan Retirement System Grows Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
SVB Wealth LLC Purchases New Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
SBI Securities Co. Ltd. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Generali Investments CEE investicni spolecnost a.s. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Banco Santander S.A. Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sanctuary Advisors LLC Sells 1,842 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Stock Price Up 3.5%Here's What Happened - MarketBeat
Biogen (NASDAQ:BIIB) Trading 3.5% HigherShould You Buy? - MarketBeat
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):